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Abstract Two cannabinoid receptors, designated neuronal (or 
CB1) and peripheral (or CB2), have recently been cloned. Activa- 
tion of CB1 receptors leads to inhibition of adenylate cyclase and 
N-type voltage-dependent Ca 2+ channels. Here we show, using a 
CB2 transfected Chinese hamster ovary cell line, that this recep- 
tor binds a variety of tricyclic cannabinoid ligands as well as the 
endogenous ligand anandamide. Activation of the CB2 receptor 
by various tricydic cannabinoids inhibits adenylate cyclase activ- 
ity and this inhibition is pertussis toxin sensitive indicating that 
this receptor is coupled to the GilGo GTP-binding proteins. Inter- 
estingly, contrary to results with CB1, anandamide did not inhibit 
the CB2 coupled adenylate cyclase activity and A9-tetrahydro - 
cannabinol had only marginal effects. These results characterize 
the CB2 receptor as a functional and distinctive member of the 
cannabinoid receptor family. 
Key words: Adenylate cyclase; Anandamide; Cannabinoid 
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1. Introduction 
Cannabinoids have been shown to inhibit adenylate cyclase 
(AC) activity in rat brain and in NI8TG2 neuroblastoma cells, 
as well as to inhibit the N-type voltage-dependent Ca 2+ chan- 
nels in the NI8TG2 cells. These cannabinoid receptor activities 
are pertussis toxin (PTX) sensitive indicating coupling to Gi/Go 
GTP-binding proteins (G proteins) [1-5]. The cloning of the 
neuronal cannabinoid receptor (CB1) [6,7] has allowed for the 
establishment of cell lines that express this receptor. Using such 
cell lines, we and others have recently shown that tricyclic 
cannabinoids, as well as the isolated endogenous cannabinoid 
ligands, anandamide, docosotetraenylethanolamide and homo- 
),-linoenylethanolamide, interact with the CB1 receptor and 
inhibit AC activity in a dose-dependent manner [5,8,9]. 
Although the original focus of cannabinoid function has 
been on the nervous ystem, it has been noted that cannabinoid 
binding sites are present in several nonneuronal tissues. Can- 
nabinoid binding sites have been localized to regions of the 
mouse and rat spleen and it has been proposed that these sites 
are located on myeloid cells or on B-cells [10,11]. In addition, 
cannabinoid receptor mRNA expression has been observed in 
both testis and spleen [7,10]. Functionally, cannabinoids have 
been shown to have suppressive effects on a variety of macro- 
phage functions in vitro [12] and to inhibit the proliferative and 
antibody-forming cell responses in spleenocytes [13]. 
A cannabinoid receptor, designated CB2 (or the peripheral 
cannabinoid receptor) has been recently cloned from the HL-60 
promyelocytic leukemia cell line [14]. It belongs to the seven 
transmembrane G protein-coupled receptor family and has a 
68% amino acid sequence homology to the CB1 receptor in the 
seven transmembrane domains, which are proposed to confer 
ligand specificity [14]. CB2 receptor expression was shown to 
increase when HL-60 cells are driven to differentiate by either 
phorbol esters or dimethylformamide [14]. Because these mate- 
rials drive HL-60 to differentiate to either macrophage- or 
granulocyte-like c lls [15], it was suggested that the CB2 recep- 
tor could have a role in the terminal differentiation of pluripo- 
tent hemopoietic stem cells. 
Very little is currently known about the structure-function 
relationship of cannabinoids with regard to the CB2 receptor, 
as well as regarding the signal transduction pathways utilized 
by this receptor. Here we report on the establishment of a 
Chinese hamster ovary (CHO) cell line that stably expresses the 
CB2 receptor. We demonstrate hat this receptor interacts with 
a variety of tricyclic annabinoid ligands and with anandamide 
and that it mediates the inhibition of AC activity through PTX 
sensitive G proteins. 
2. Materials and methods 
2.1. Materials 
The cannabinoids HU-243, HU-210, HU-211, Ag-tetrahydrocannabi- 
nol (A9-THC), and anandamide have been previously described [5,16- 
18]. The synthesis of the cannabinoids HU-293 and HU-293a will be 
described separately. For formulae of tricyclic cannabinoids, ee Fig. 
1. Cannabinoids were kept in ethanol and diluted before use in 50 
mg/ml fatty acid free-bovine serum albumin (FAF-BSA) as described 
[16]. The phosphodiesterase inhibitors, 1-methyl-3-isobutylxanthine 
(IBMX) and Ro-20-1724 were from Calbiochem (La Jolla, CA). All 
other materials were previously described [5]. 
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2.2. Cell transfection a d culture 
The human CB2 receptor cDNA inserted into the mammalian ex- 
pression vector pcDNA1 was kindly provided by Dr. Sean Munro 
(Cambridge, UK). Parental CHO-K1 cells (American Type Tissue Cul- 
ture Collection, Rockville, MD) were transfected with pcDNA1-CB2 
along with the pRC/cmv vector carrying the neomycin resistance gene 
(Invitrogen Co., San Diego, CA) using the lipofectamine transfection 
method (Gibco-BRL). Clones resistant to G418 (1 mg/ml) were ana- 
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lyzed for their capacity to bind [3H]HU-243. The CHO-CB2 receptor 
cell line isolated was cultured in Dulbecco's modified Eagle's medium 
(DMEM) supplemented with 10% fetal calf serum, 2mM glutamine, 
nonessential amino acids, 0.2 mg/ml G418, 100 U/ml penicillin and 100 
pg/ml streptomycin in a humidified atmosphere consisting of 5% CO2 
and 95% air, at 37°C. 
2.3. Cannabinoid receptor-binding and A C assays 
The binding of the labeled high affinity cannabinoid ligand [3H]HU- 
243 (54 Ci/mmol) was carried out in siliconized Eppendorf tubes as 
described [5,17]. AC assay was performed by labeling cells in 24-well 
plates for 3 h with 5 pCi/ml of [3H]adenine (10.3 Ci/mmol). Medium was 
replaced with 0.485 ml of DMEM containing 20 mM HEPES (pH 7.4), 
1 mg/ml FAF-BSA, 0.1 mM IBMX and 0.5 mM Ro-2~1724. Cannabi- 
noids were added in 5/tl containing 50 mg/ml FAF-BSA. Forskolin was 
added (in 10/zl) to a final concentration f 1 stM. Cells were maintained 
at 37°C for 10 min. Medium was removed and reaction terminated with 
1 ml of 2.5% perchloric acid followed by neutralization a d column 
separation ofthe [3H]cAMR AC activity was determined according to 
the amount of [3H]cAMP detected. For additional information see 
Vogel et al. [5]. Individual values were calculated interms of percentage 
of control (i.e. in the absence of ligand) for each specific experiment. 
Results are expressed asmeans + S.E.M. of these normalized values. 
Generation of plots, determination f binding parameters (Kd, Ki, IC50, 
and Bronx) and ECs0 values were performed as described [5,9]. 
3. Results 
To a establish a stable cell line expressing the CB2 receptor, 
CHO-K1 cells were transfected with the complete cDNA se- 
quence ncoding for the CB2 receptor in pcDNA1 simultane- 
ously with the vector pRC/cmv to provide drug resistance. 
G418 resistant colonies were screened for binding of the labeled 
high affinity cannabinoid ligand [3H]HU-243. One positive 
clone (with Bma x of 525 + 6 fmol/mg of protein) was chosen and 
used for this study. 
The Scatchard analysis of the binding of [3H]HU-243 to 
crude membranes of the cells of the clone revealed a Kd value 
~C5H 11 
A9-THC 
of 61 + 5 pM. The competition binding assays performed with 
a variety of tricyclic cannabinoid ligands and with the en- 
dogenous ligand anandamide are shown in Fig. 2. The most 
effective displacer of [3H]HU-243 binding to CHO-CB2 cell 
membranes was HU-243 itself with a Kd value of 47 + 7 pM. 
This value is similar to that obtained by the Scatchard analysis 
described above. The other ligands investigated, HU-210, HU- 
293a, HU-293, A9-THC, and anandamide gave K~ values of 
147+7pM,  20+4nM,  30+4,39+5nM,  and85-+ 13nM, 
respectively. HU-211, the enantiomer of HU-210, found to be 
inactive on the CB1 receptor [5] was also inactive as a displacer 
of [3H]HU-243 from the CB2 receptor. No binding was ob- 
served to nontransfected CHO-K1 cells (data not shown). 
Activation of the cannabinoid receptor of brain and of 
NIsTG 2 cells inhibits the forskolin or secretin stimulation ofAC 
[1-3,5,6,20]. We have therefore investigated if the CB2 receptor 
would have a similar activity. We have assessed the ability of 
several tricyclic cannabinoid erivatives to inhibit the fors- 
kolin-stimulated AC activity in CHO-CB2 cells (Fig. 3). Indeed, 
about 50% of the forskolin-stimulated AC activity could be 
inhibited by several tricyclic cannabinoids. HU-210 had the 
strongest agonistic activity with an ECs0 value of 1 + 0.6 nM. 
HU-293a was less active than HU-210 (ECs0 of 8 + 3 nM) while 
HU-293, the acetate of HU-293a, was slightly less active with 
an ECso value of 47 + 4 nM. The inhibition of AC by HU-210 
and by HU-293a was not affected by the addition of I0 pM of 
the CB1 antagonist, SR141716A, [9,21] (15-20 s before agonist 
addition), demonstrating that this antagonist is selective for 
CB 1 and does not interact with CB2 (data not shown). Interest- 
ingly, A9-THC and anandamide, materials that bind to both 
CB2 and CB1 receptors and which have been shown to inhibit 
AC in N18TG2 and in CHO-CB1 cells [5,8,9,20], did not signif- 
icantly inhibit AC activity in the forskolin activated CHO-CB2 
cells. 
C6H13 
HU-210, (-) enantiomer 
HU-211, (+) enantiomer 
CH20H 
CsH13 
COOH 
C6H13 
HU-243 HU-293, R = COCH3 
HU-293a,  R = H 
Fig. 1. Formulae of tricyclic cannabinoids. 
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Fig. 2. Tricyclic annabinoids and anandamide compete with binding 
of [3H]HU-243 to CB2 receptor in CHO-CB2 cells. Binding of [3H]HU- 
243 (0.3 nM final) was assayed in the presence ofthe indicated concen- 
trations of cannabinoids. 100% specific binding was obtained by sub- 
tracting the background inthe presence of10/~M HU-210 (ca. 400 cpm, 
less than 35% of total binding). Phenylmethylsulfonyl fluoride (PMSF) 
at 0.15 mM was added to the binding assay with anandamide to protect 
it from degradation [19]. PMSF did not affect binding of the tricyclic 
cannabinoids. Data are the mean + S.E.M. of three independent exper- 
iments (performed induplicate). 
In the above-described xperiment, we have used forskolin 
to stimulate AC activity. Similar observations were also ob- 
tained when AC activation was performed following a 2 h 
preincubation with cholera toxin (CTX). In the experiment 
described in Fig. 4, we show that HU-210 at 0.1 /.tM and 
HU-293a at 1 ltM inhibited CTX stimulated AC activity by 
61% and 48%, respectively. These levels of inhibition are similar 
to those observed when AC was stimulated with forskolin. On 
the other hand as described above, A9-THC was much less 
potent in inhibiting AC activity. 1/.tM of A9-THC inhibited AC 
by only 18%. This level of inhibition ismuch lower than the one 
obtained with the CB 1 receptor with equivalent concentrations 
of Ag-THC [5]. The nature of the weak inhibition of AC by 
Ag-THC and anandamide via the CB2 receptor is under investi- 
gation. 
To determine the class of the G proteins involved in the 
inhibition of AC by the CB2 receptor activation, we have 
treated CHO-CB2 cells with 100 ng/ml of PTX for 20 h prior 
to AC assay. As shown in Fig. 5, the inhibition of AC by 0.1 
/~M HU-210 or by 1/IM HU-293a was completely abolished 
by PTX pretreatment, indicating involvement of the Gi/Go G 
proteins in the CB2 coupled inhibition of AC activity. 
4. Discussion 
We have prepared a cell line that stably expresses the CB2 
cannabinoid receptor. The expressed CB2 receptor has the abil- 
ity to bind Ag-THC and a number of synthetic tricyclic annabi- 
noids as well as anandamide. The binding potencies of HU-243, 
HU-210, A9-THC, and anandamide were found to be similiar 
to values reported for the CB1 receptor [5,16,17]. In addition, 
we have shown that tricyclic annabinoids were able to mediate 
inhibition of forskolin stimulated AC activity in these cells. This 
inhibition is PTX sensitive demonstrating that the peripheral 
cannabinoid receptor, CB2, is similar to the CB1 receptor in its 
ability to couple to the G~/Go G protein effector-signaling sys- 
tem. Tricyclic cannabinoids id not bind and had no effect on 
AC activity in parental CHO cells [5]. We therefore conclude 
that the cannabinoid effect on AC activity is being mediated by 
the expressed CB2 receptor in the transfected cells. These re- 
sults are consistent with a recent report indicating that AC 
inhibition (via CB 1) is indeed coupled to cannabinoid receptors 
as opposed to alternate signal transduction pathways that ap- 
pear to be stimulated via nonreceptor-mediated cannabinoid- 
induced effects [3]. 
Analysis of the structur~activity relationship of the various 
tricyclic cannabinoids tested could demonstrate which struc- 
tural elements of the tricyclic ligand can influence binding. 
Indeed, small modifications based on the basic structure of 
Ag-THC can increase or decrease binding to the cannabinoid 
receptors by almost 1000-fold and markedly change the capac- 
ity of the cannabinoids to inhibit AC. For example, the addition 
of a hydroxyl group at the C-11 position in AS-THC (which 
parallels A9-THC activity) and the conversion of the hydropho- 
bic pentyl carbon chain into a 1,1-dimethylheptyl chain (i.e. 
converting AS-THC to HU-210) led to high affinity ligand 
receptor interaction. These modifications ofAg-THC have also 
greatly increased ligand affinity toward the cannabinoid recep- 
tor of brain [18]. 
In agreement with the binding studies, HU-210 and HU-293a 
were effective agonists and gave similar inhibition of AC; their 
ECs0 values being in the concetration range of their Ki values. 
On the other hand, A9-THC and anandamide demonstrated a 
much lower ability to inhibit AC activity even though they were 
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Fig. 3. Tricyclic annabinoids inhibit he forskolin-stimulated AC activ- 
ity in CHO-CB2. Cannabinoids were added at the indicated concentra- 
tions. PMSF at 0.15 mM was present in the anandamide assay and did 
not have any effect by itself on AC activity. The amount of [3H]cAMP 
in the absence of forskolin was subtracted. Data are the mean _+ S.E.M. 
of three to four independent experiments (performed induplicate). 
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able to bind to the CB2 receptor. For example, the affinity of 
Ag-THC (Ki of 39 nM) to this receptor was similar to some of 
the active tricyclic cannabinoids (e.g. HU-293a with a Ki of 20 
nM). This raises the possibility that A9-THC and anandamide 
serve as weak partial agonists of the CB2 receptor (i.e. ligands 
which bind but do not effectively activate the receptor) indicat- 
ing a difference in the signal transduction compared with the 
previously reported inhibition of AC by A9-THC and anan- 
damide for the CB1 receptor [5,8,9]. Indeed, preliminary exper- 
iments have shown that A9-THC can antagonize the AC inhibi- 
tion induced by HU-293 or HU-293a through the CB2 receptor 
(data not shown). This result suggests that use of marijuana (in 
which the active component is mainly Ag-THC) could have 
different effects on AC activity in the nervous and peripheral 
systems due to the differential ability of A9-THC to mediate its 
effects depending on the receptor with which it interacts. It is 
interesting to note that anandamide, as well as its two en- 
dogenous analogues docosotetraenylethanolamide an  homo- 
7-1inoenylethanolamide, have been shown to act as partial ag- 
onists at the CB1 receptor in cultured N18TG 2 neuroblastoma 
cells [4,9,20] and that anandamide and docosotetraenyletha- 
nolamide were shown to have partial agonistic effects in vivo 
as well [20]. 
The presence of multiple cannabinoid receptors and the elu- 
cidation of their signal transduction pathways hould allow for 
the identification of cannabinoid effects according to which 
cannabinoid receptor is being activated. Because CB2 has been 
found in spleen and has been implicated to be present in cells 
of the immune system, the immune modulatory effects of can- 
nabinoids are possibly mediated through this receptor. Our 
work demonstrates that activation of the CB2 receptor can 
mediate inhibition of AC activity. Recent work [13,22] indeed 
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Fig. 4. Cannabinoids inhibit he CTX-stimulated AC activity. CHO- 
CB2 cells were preincubated for 2 h in the presence of 100 ng/ml of 
CTX. This was followed by the addition of phosphodiesterase inhib- 
itors and cannabinoids. The background, efined as the level of cAMP 
in cells prior to the addition of phosphodiesterase inhibitors (ca. 1500 
cpm), was subtracted. Control, represented as100%, was equivalent to
ca. 5500 cpm. Data are the mean _+ S.E.M. of three independent exper- 
iments (performed in duplicate). **P < 0.001, significantly different 
from control according to Student's t-test. 
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Fig. 5. Pretreatment of CHO-CB2 cells with PTX blocks the inhibition 
of AC activity by cannabinoids. CHO-CB2 cells were preincubated for 
20 h with 100 ng/ml of PTX (fresh PTX was supplemented upon the 
addition of [3H]adenine). The forskolin-stimulated AC activity in the 
absence of PTX and cannabinoids is represented as 100% and was 
equivalent ca. 2150 cpm. The basal evel was ca. 300 cpm. Data are the 
mean + S.E.M. of three independent experiments (performed in dupli- 
cate). *P < 0.005, significantly different from control according to Stu- 
dent's t-test. 
demonstrates that cannabinoids inhibit cAMP formation in 
spleenocytes and that this effect is associated with inhibition of 
the humoral immune response in spleen cells. The development 
of selective agonists and antagonists should allow for the spe- 
cific elucidation of the effects mediated by each cannabinoid 
receptor. 
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